Literature DB >> 30868332

Two- and three-dimensional QSAR studies on hURAT1 inhibitors with flexible linkers: topomer CoMFA and HQSAR.

Tingting Zhao1, Zean Zhao1, Fengting Lu1, Shan Chang2, Jiajie Zhang1, Jianxin Pang1, Yuanxin Tian3.   

Abstract

hURAT1 (human urate transporter 1) is a successful target for hyperuricemia. Recently, the modification work on hURAT1 inhibitors showed that the flexible linkers would benefit biological activity. The study aimed to investigate the contribution of the linkers and give modification strategies on this kind of structures based on QSAR models (HQSAR and topomer CoMFA). The most effective HQSAR and topomer CoMFA models were generated by applying the training set containing 63 compounds, with the cross-validated q2 values of 0.869/0.818 and the non-cross-validated correlation coefficients r2 of 0.951/0.978, respectively. The Y-randomization test was applied to ensure the robustness of the models. The external predictive correlation coefficient (rpred2) grounded on the external test set (21 compounds) of two models was 0.910 and 0.907, respectively. In addition, the models were validated by Golbraikh-Tropsha and Roy methods, as well as other statistical metrics. The results showed that both models were reliable. Topomer CoMFA steric/electrostatic contours and HQSAR atomic contribution maps illustrated the structural features which governed their inhibitory potency. The dependable results could provide important insights to guide the designing of more potential hURAT1 inhibitors.

Entities:  

Keywords:  HQSAR; Hyperuricemia; Topomer COMFA; hURAT1 inhibitors

Year:  2019        PMID: 30868332     DOI: 10.1007/s11030-019-09936-5

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  32 in total

1.  R-group template CoMFA combines benefits of "ad hoc" and topomer alignments using 3D-QSAR for lead optimization.

Authors:  Richard D Cramer
Journal:  J Comput Aided Mol Des       Date:  2012-06-04       Impact factor: 3.686

Review 2.  Fragment-based QSAR: perspectives in drug design.

Authors:  Lívia B Salum; Adriano D Andricopulo
Journal:  Mol Divers       Date:  2009-01-31       Impact factor: 2.943

3.  Virtual screening for R-groups, including predicted pIC50 contributions, within large structural databases, using Topomer CoMFA.

Authors:  Richard D Cramer; Phillip Cruz; Gunther Stahl; William C Curtiss; Brian Campbell; Brian B Masek; Farhad Soltanshahi
Journal:  J Chem Inf Model       Date:  2008-11       Impact factor: 4.956

4.  The rm2 metrics and regression through origin approach: reliable and useful validation tools for predictive QSAR models (Commentary on 'Is regression through origin useful in external validation of QSAR models?').

Authors:  Kunal Roy; Supratik Kar
Journal:  Eur J Pharm Sci       Date:  2014-05-29       Impact factor: 4.384

5.  Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).

Authors:  Ying Pan; Ling-Dong Kong
Journal:  Expert Opin Ther Pat       Date:  2016-07-30       Impact factor: 6.674

6.  Molecular analysis of the SLC22A12 (URAT1) gene in patients with primary gout.

Authors:  J Vázquez-Mellado; A L Jiménez-Vaca; S Cuevas-Covarrubias; V Alvarado-Romano; G Pozo-Molina; R Burgos-Vargas
Journal:  Rheumatology (Oxford)       Date:  2006-07-11       Impact factor: 7.580

7.  Molecular identification of a renal urate anion exchanger that regulates blood urate levels.

Authors:  Atsushi Enomoto; Hiroaki Kimura; Arthit Chairoungdua; Yasuhiro Shigeta; Promsuk Jutabha; Seok Ho Cha; Makoto Hosoyamada; Michio Takeda; Takashi Sekine; Takashi Igarashi; Hirotaka Matsuo; Yuichi Kikuchi; Takashi Oda; Kimiyoshi Ichida; Tatsuo Hosoya; Kaoru Shimokata; Toshimitsu Niwa; Yoshikatsu Kanai; Hitoshi Endou
Journal:  Nature       Date:  2002-04-14       Impact factor: 49.962

8.  Molecular Modeling Study on Diazine Indole Acetic Acid Derivatives for CRTH2 Inhibitory Activity.

Authors:  Sathya Babu; Mottadi Rupa; Santhosh Kumar Nagarajan; Honglae Sohn; Thirumurthy Madhavan
Journal:  Comb Chem High Throughput Screen       Date:  2016       Impact factor: 1.339

Review 9.  2016 updated EULAR evidence-based recommendations for the management of gout.

Authors:  P Richette; M Doherty; E Pascual; V Barskova; F Becce; J Castañeda-Sanabria; M Coyfish; S Guillo; T L Jansen; H Janssens; F Lioté; C Mallen; G Nuki; F Perez-Ruiz; J Pimentao; L Punzi; T Pywell; A So; A K Tausche; T Uhlig; J Zavada; W Zhang; F Tubach; T Bardin
Journal:  Ann Rheum Dis       Date:  2016-07-25       Impact factor: 19.103

10.  Potent human uric acid transporter 1 inhibitors: in vitro and in vivo metabolism and pharmacokinetic studies.

Authors:  Michael F Wempe; Janet W Lightner; Bettina Miller; Timothy J Iwen; Peter J Rice; Shin Wakui; Naohiko Anzai; Promsuk Jutabha; Hitoshi Endou
Journal:  Drug Des Devel Ther       Date:  2012-11-08       Impact factor: 4.162

View more
  1 in total

1.  CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia.

Authors:  Ze-An Zhao; Yu Jiang; Yan-Yu Chen; Ting Wu; Qun-Sheng Lan; Yong-Mei Li; Lu Li; Yang Yang; Cui-Ting Lin; Ying Cao; Ping-Zheng Zhou; Jia-Yin Guo; Yuan-Xin Tian; Jian-Xin Pang
Journal:  Acta Pharmacol Sin       Date:  2021-03-25       Impact factor: 6.150

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.